Could a simple steroid shot before C-Section protect newborns from low blood sugar?

NCT ID NCT06716918

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This trial asks whether giving mothers a corticosteroid injection before a planned cesarean section at 37-38 weeks of pregnancy can lower the chance of their newborns developing hypoglycemia (low blood sugar). It will compare the rate of neonatal hypoglycemia in infants whose mothers received the steroid versus those who did not. The study includes 188 women with singleton pregnancies scheduled for early-term C-sections, excluding those with diabetes or other risk factors. The goal is to see if this common prenatal treatment offers a protective benefit for babies born at this stage.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Corticosteroid injection (betamethasone or dexamethasone)
What this could lead to
If effective, giving corticosteroids before planned early-term C-sections could lower the risk of newborn hypoglycemia, improving infant health outcomes.
What could go wrong
This is a single-center trial with 188 participants, so results may not apply broadly. Corticosteroids carry potential risks for both mother and baby, and the benefit may not be confirmed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

188 people

The number who actually took part.

Started

Jan 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women Health Hospital, Faculty of medicine, Assiut university

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Female participants only

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- 1. Women with singleton pregnancies at 37-38 weeks of gestation (early-term) scheduled for planned cesarean sections. 2\. Participants who have received antenatal corticosteroids prior to cesarean section as part of their prenatal care. Exclusion Criteria: * 1\. Women delivering before 37 weeks or after 39 weeks of gestation would be excluded, as the study focuses on early-term deliveries. 2\. Women with any form of diabetes, including pre-existing type 1 or type 2 diabetes, and gestational diabetes. This ensures that the study focuses on non-diabetic populations, as diabetes can independently affect neonatal glucose regulation and complicate the assessment of hypoglycemia risk due to corticosteroids. 3\. Women with severe maternal health such as preeclampsia, chronic hypertension, or other systemic illnesses, might be excluded to avoid confounding variables. 4\. Women who did not complete the full course of antenatal corticosteroids may be excluded, as the effect of partial doses could differ from complete treatment. 5\. Women with multiple gestations (e.g., twins or triplets) may be excluded due to the added complexity of multiple-birth pregnancies and their unique risk. 6\. Neonates with known congenital anomalies, genetic disorders, or other pre-existing medical conditions that could affect glucose metabolism

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antenatal corticosteroids are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Women Health Hospital, Faculty of medicine, Assiut university

    Asyut, Egypt